Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C.

PubWeight™: 2.05‹?› | Rank: Top 2%

🔗 View Article (PMID 17258733)

Published in Gastroenterology on November 29, 2006

Authors

David E Kaplan1, Kazushi Sugimoto, Kimberly Newton, Mary E Valiga, Fusao Ikeda, Ayse Aytaman, Frederick A Nunes, Michael R Lucey, Barbara A Vance, Robert H Vonderheide, K Rajender Reddy, Jane A McKeating, Kyong-Mi Chang

Author Affiliations

1: Gastroenterology Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

Articles citing this

Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80

Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45

Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95

Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57

Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol (2010) 2.45

Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 2.02

Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 1.89

Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78

Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol (2007) 1.50

Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis (2009) 1.49

Spontaneous clearance of hepatitis C virus in vertically infected children. Eur J Pediatr (2011) 1.47

Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med (2012) 1.43

Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol (2008) 1.33

Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis (2008) 1.30

In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25

Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol (2008) 1.22

Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol (2010) 1.18

Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16

Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther (2013) 1.15

Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15

Hepatitis C virus: virology and life cycle. Clin Mol Hepatol (2013) 1.15

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13

Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal (2014) 1.10

Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol (2007) 0.99

Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology (2008) 0.97

Natural Killer Cells in Viral Hepatitis. Cell Mol Gastroenterol Hepatol (2015) 0.96

Hepatitis C virus promotes T-helper (Th)17 responses through thymic stromal lymphopoietin production by infected hepatocytes. Hepatology (2013) 0.95

A new insight into hepatitis C vaccine development. J Biomed Biotechnol (2010) 0.94

The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J Virol (2013) 0.93

Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol (2008) 0.92

"Negative vaccination" by specific CD4 T cell tolerisation enhances virus-specific protective antibody responses. PLoS One (2007) 0.90

The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89

Polyfunctional type-1, -2, and -17 CD8⁺ T cell responses to apoptotic self-antigens correlate with the chronic evolution of hepatitis C virus infection. PLoS Pathog (2012) 0.89

Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection. Clin Exp Immunol (2008) 0.89

Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87

NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis (2011) 0.86

Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol (2016) 0.86

Adaptive immune response during hepatitis C virus infection. World J Gastroenterol (2014) 0.85

Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS One (2008) 0.83

CD8(+) T-Cell Responses in Acute Hepatitis C Virus Infection. Front Immunol (2014) 0.83

Frequency of gC1qR+CD4+ T cells increases during acute hepatitis C virus infection and remains elevated in patients with chronic infection. Clin Immunol (2009) 0.83

Induction of Multiple Immune Regulatory Pathways with Differential Impact in HCV/HIV Coinfection. Front Immunol (2014) 0.82

Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles. Clin Vaccine Immunol (2008) 0.82

HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin. World J Gastroenterol (2014) 0.81

A spatial view of the CD8+ T-cell response: the case of HCV. Rev Med Virol (2011) 0.79

Hepatitis C Viral Infection in Children: Updated Review. Pediatr Gastroenterol Hepatol Nutr (2016) 0.79

Immunological changes in different patient populations with chronic hepatitis C virus infection. World J Gastroenterol (2016) 0.77

Destruction of lymphoid organ architecture and hepatitis caused by CD4+ T cells. PLoS One (2011) 0.77

Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection. J Viral Hepat (2013) 0.77

Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77

Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77

Distinct features in natural history and outcomes of acute hepatitis C. J Clin Gastroenterol (2015) 0.76

T and B cells in hepatitis C virus control: what they do and when they fail. Gastroenterology (2007) 0.76

Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model. J Virol (2017) 0.75

Adaptive immunity to hepatitis C virus. Viruses (2009) 0.75

Hepatitis infection in the treatment of opioid dependence and abuse. Subst Abuse (2008) 0.75

Articles by these authors

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01

Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30

Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45

EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell (2012) 5.77

The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98

Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90

Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92

Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84

Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71

Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69

CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47

Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45

Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30

Colonoscopy training in gastroenterology fellowships: determining competence. Gastrointest Endosc (2009) 3.15

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med (2012) 3.15

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13

Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10

Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09

Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09

Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95

Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest (2005) 2.84

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood (2003) 2.83

Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77

Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65

Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58

Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57

Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51

Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol (2010) 2.45

Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology (2003) 2.45

Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43

First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA (2012) 2.29

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med (2012) 2.22

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17

Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol (2004) 2.16

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13

Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell (2011) 2.10

Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06

Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04

Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci (2009) 1.96

Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther (2010) 1.94

Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92

Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87

Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87

The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87

Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83

Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood (2002) 1.82

Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76

Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74

Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72

Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72

Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71

A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl (2011) 1.69

Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68

Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2004) 1.68

Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67

Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67

Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood (2010) 1.66

Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63

Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol (2008) 1.63

RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood (2003) 1.62

CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62

Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 1.61

Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61

Transplantation: impact of pretransplant renal insufficiency. Liver Transpl (2008) 1.58

Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58

Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58

Phytobezoars. Intern Med (2008) 1.57